 | | Vol. 13.40 – 29 October, 2021 |
| |
|
|
| The authors identified K2P18.1 as a central translator of the T cell receptor signal into the thymus-derived Treg selection process.
[Cell Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| FVB/NJ mice were hydrodynamically injected with AKT/Ras and Sleeping Beauty transposon to induce hepatocellular carcinoma. Mini-circle and Sleeping Beauty were used to overexpress microRNA-206 in Kupffer cells of mice.
[Gut] |
|
|
|
| Investigators assessed the effects of Nox2 absence on monocyte-derived macrophages in gp91phox-/y mice during zymosan-induced peritonitis.
[Blood] |
|
|
|
| Researchers showed that the immune deficiency pathway, but not the Toll pathway, was responsible for attraction and invasion of hemolymph-borne macrophages across the blood-brain barrier during pupal stages.
[Science Advances] |
|
|
|
| Investigators showed that optineurin was upregulated in human and mouse dendritic cell (DC) maturation, and that deletion of Optn in mice via CD11c-Cre attenuated DC maturation and impaired the priming of CD4+ T cells, thus ameliorating autoimmune symptoms such as experimental autoimmune encephalomyelitis.
[Nature Communications] |
|
|
|
| Scientists showed that chemotherapy-induced anti-cancer immunity was suppressed by the tumor microenvironment through production of the cytokine IL-6.
[Nature Communications] |
|
|
|
| The authors showed that Evokin was present in hemocytes and fat-body cells, and mRNA expression increased significantly after immune priming.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| A type of smart exosomes was developed, in which the exosome surface was functionally engineered with CD62L and OX40L by forced expression of the genes in the donor cells.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Scientists developed a novel nanocomposite, polyethyleneimine-modified dendritic mesoporous silica nanoparticles loaded with microRNA-125a to synergistically enhance immune response and immunosuppression reversion, ultimately generating a tumoricidal environment.
[Journal of Nanobiotechnology] |
|
|
|
| Researchers focused on the BCL-2 specific inhibitor venetoclax and its effects following short-term and long-term BCL-2 blockade on T cell subsets.
[Cell Death & Disease] |
|
|
|
| Investigators established and verified an in vitro experimental system for the direct co-culture of cell pellets prepared from mouse auricular chondrocytes and macrophages polarized into four phenotypes.
[Scientific Reports] |
|
|
|
| The authors investigated supportive therapy potential of acidophilus milk and propolis extract in the mouse xenograft breast cancer model.
[Cytokine] |
|  |
|
|
|
| Scientists describe the current knowledge of the effects of aging on the immune system and the cerebral vasculature and how these changes alter the immune response to stroke and vascular dementia in animal and human studies.
[Molecular Psychiatry] |
|
|
|
| Monogenic immune disorders provide unprecedented insights into the consequences of disrupting single genes in humans, thereby informing the understanding of fundamental immune function and disease.
[Current Opinion in Immunology] |
|
|
|
|
| Concert Pharmaceuticals, Inc. announced that it has completed patient enrollment in THRIVE-AA1, the first Phase III clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.
[Concert Pharmaceuticals, Inc.] |
|
|
|
| Immutep Limited announced it has received positive feedback from the European Medicines Agency (EMA) regarding its clinical development program for lead product candidate, eftilagimod alpha, including the planned Phase III trial in MBC.
[Immutep Limited] |
|
|
|
| Incyte announced the validation of the European Marketing Authorization Application for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults with non-segmental vitiligo with facial involvement.
[Incyte] |
|
|
|
|
| November 12 -15, 2021
Virtual |
|
|
|
|
|
| | Malm̦, Sweden РLund University |
|
|
|
| | Calgary, Alberta, Canada – University of Calgary |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
